Advancing quality control measures vital for cell and gene therapy development
Despite the high level of specialisation involved in cell and gene therapies, quality control (QC) for these drugs is still done with pen and paper.
Cell & Gene Therapy
NHS investment critical to drive cell and gene therapy research
Gene therapy for rare neuropathy displays potential in NIH trial
Can Gilead shake up the ASCT-ineligible large B-cell lymphoma market?
Mapping endpoints: building gene therapy trials for the future
Five gene therapy trial readouts to watch in the first half of 2023
Enlivex receives approval for Phase I/II solid tumour trial in Israel
Nanoscope doses first subject in Phase II Stargardt disease trial
